Overview

Financials

News Ideas Discussions Technicals Forecast Seasonals Options

CADL fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪297.61 M‬USD

—

−1.33USD

2002

Paul-Peter Tak

candeltx.com

About

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Ownership

‪‪50.10 M‬‬

Free Float shares

‪‪36.44 M‬‬ (72.73%)

Closely held shares

‪‪13.66 M‬‬ (27.27%)

Free Float shares

‪‪36.44 M‬‬ (72.73%)

Closely held shares

‪‪13.66 M‬‬ (27.27%)

Capital structure

Market cap

‪‪297.61 M‬‬

Debt

‪‪10.91 M‬‬

Cash & equivalents

‪‪92.17 M‬‬

Enterprise value

‪‪216.36 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪297.61 M‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

—

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

—

Valuation ratios

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Growth and Profitability

Company’s recent performance and margins

Performance

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪‪−24.00 M‬‬

‪‪−16.00 M‬‬

‪‪−8.00 M‬‬

‪0.00‬

‪‪8.00 M‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−9.00 M‬‬

‪‪−4.50 M‬‬

‪0.00‬

‪‪4.50 M‬‬

‪‪9.00 M‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−2.50 M‬‬

‪0.00‬

‪‪2.50 M‬‬

‪‪5.00 M‬‬

‪‪7.50 M‬‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪0.00‬

Actual

Estimate

Earnings

Next:Sep 3, 2025

Q2 '24

Q3 '24

Q4 '24

Q1 '25

Q2 '25

‪−0.75‬

‪−0.50‬

‪−0.25‬

‪0.00‬

‪0.25‬

Actual

Estimate

Dividends

Dividend yield, history and sustainability

No dividends

CADL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪‪−40.00 M‬‬

‪0.00‬

‪‪40.00 M‬‬

‪‪80.00 M‬‬

‪‪120.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪25.00 M‬‬

‪‪50.00 M‬‬

‪‪75.00 M‬‬

‪‪100.00 M‬‬

Assets

Liabilities